Equities analysts forecast that Unum Therapeutics Inc (NASDAQ:UMRX) will report sales of $4.12 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the lowest sales estimate coming in at $3.83 million and the highest estimate coming in at $4.41 million. Unum Therapeutics posted sales of $3.80 million in the same quarter last year, which suggests a positive year-over-year growth rate of 8.4%. The firm is expected to issue its next earnings results on Thursday, March 26th.
On average, analysts expect that Unum Therapeutics will report full year sales of $10.89 million for the current year, with estimates ranging from $10.00 million to $11.62 million. For the next fiscal year, analysts anticipate that the business will report sales of $15.26 million, with estimates ranging from $5.00 million to $25.33 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.07). The firm had revenue of $1.02 million during the quarter, compared to the consensus estimate of $4.41 million. Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new stake in Unum Therapeutics in the 3rd quarter worth approximately $31,000. Wedbush Securities Inc. acquired a new position in shares of Unum Therapeutics during the third quarter worth approximately $48,000. Susquehanna International Group LLP acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $62,000. Jane Street Group LLC acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $132,000. Finally, Paloma Partners Management Co acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $227,000. Hedge funds and other institutional investors own 43.02% of the company’s stock.
UMRX traded up $0.02 on Monday, hitting $0.69. The company had a trading volume of 370,182 shares, compared to its average volume of 148,198. The company’s fifty day moving average price is $1.06 and its 200 day moving average price is $1.94. Unum Therapeutics has a 1-year low of $0.58 and a 1-year high of $6.64. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.96 and a quick ratio of 1.96. The stock has a market cap of $21.05 million, a price-to-earnings ratio of -0.49 and a beta of 1.01.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Article: Limitations of the P/E Growth ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.